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Abstract 
 
Emerging evidence suggests that both adult cardiac cell and the cardiac stem/progenitor 
cell (CSPC) compartments are involved in the patho-physiology of diabetic 
cardiomyopathy (DCM). We evaluated whether early administration of Resveratrol, a 
natural antioxidant polyphenolic compound, in addition to improving cardiomyocyte 
function, exerts a protective role on (i) the progenitor cell pool, and (ii) the myocardial 
environment and its impact on CSPCs, positively interfering with the onset of DCM 
phenotype.  
Adult Wistar rats (n=128) with streptozotocin-induced type-1 diabetes were either 
untreated (D group; n=54) or subjected to administration of trans-Resveratrol (i.p. injection: 
2.5 mg/Kg/day; DR group; n=64). Twenty-five rats constituted the control group (C). After 
1, 3 or 8 weeks of hyperglycemia, we evaluated cardiac hemodynamic performance, and 
cardiomyocyte contractile properties and intracellular calcium dynamics. Myocardial 
remodeling and tissue inflammation were also assessed by morphometry, 
immunohistochemistry and immunoblotting. Eventually, the impact of the diabetic “milieu” 
on CSPC turnover was analyzed in co-cultures of healthy CSPCs and cardiomyocytes 
isolated from D and DR diabetic hearts.  
In untreated animals, cardiac function was maintained during the first 3 weeks of 
hyperglycemia, although a definite ventricular remodeling was already present, mainly 
characterized by a marked loss of CSPCs and adult cardiac cells. Relevant signs of 
ventricular dysfunction appeared after 8 weeks of diabetes, and included: 1) a significant 
reduction in ±dP/dt in comparison with C group, 2) a prolongation of isovolumic 
contraction/relaxation times, 3) an impaired contraction of isolated cardiomyocytes 
associated with altered intracellular calcium dynamics. Resveratrol administration reduced 
atrial CSPC loss, succeeded in preserving the functional abilities of CSPCs and mature 
cardiac cells, improved cardiac environment by reducing inflammatory state and 
decreased unfavorable ventricular remodeling of the diabetic heart, leading to a marked 
recovery of ventricular function. These findings indicate that RSV can constitute an 
adjuvant therapeutic option in DCM prevention and treatment. 
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Diabetic Cardiomyopathy 
 
Cardiovascular disease represents the major cause of morbidity and mortality in 
diabetic patients [1]. Accumulating data from experimental, pathological, 
epidemiological, and clinical studies have shown that diabetes mellitus results in 
cardiac functional and structural changes which develop independently of 
hypertension, coronary artery disease, or any other known cardiac diseases, 
supporting the existence of a specific diabetic cardiomyopathy (DCM) [2,3]. The 
concept of DCM was first introduced by Rubler et al. [4] in 1972, who reported 
the autopsy data from four patients with diabetic renal microangiopathy and 
dilated left ventricles in the absence of other common causes.  
By definition, diabetic cardiomyopathy is a distinct primary disease 
process which occurs independently of common comorbidities and secondary to 
a metabolic insult, resulting in structural and functional abnormalities of the 
myocardium leading to heart failure (HF).  
Despite the potential importance of this disease entity, the complex and 
multifactorial nature of the cellular and molecular perturbation that predispose to 
altered myocardial structure and function remains incompletely understood. 
 
Pathophysiologic mechanisms of diabetic cardiomyopathy  
The pathogenesis of diabetic cardiomyopathy is multifactorial (Fig. 1). 
Several hypotheses have been proposed, including autonomic dysfunction, 
metabolic derangements, abnormalities in Ca2+ homeostasis, alteration in 
structural protein, and interstitial fibrosis. The variety of proposed mechanisms 
advanced for the pathogenesis of diabetic cardiomyopathy likely reflects the 
complex nature of this disease.  
The metabolic environment, characterized by hyperglycemia, 
hyperinsulinemia, and hyperlipidemia (usually in the form of increased 
triglycerides and non-esterified fatty acids – NEFAs), in which diabetic heart 
functions, certainly triggers a substantial amount of cellular, structural and 
functional alterations progressively leading to DCM phenotype.  
In particular, hyperglicemia is considered to be a central driver in the 
pathophysiology of diabetic cardiomyopathy, in both type-1 and type-2 diabetes. 
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Type 1 diabetes differs principally from type 2 diabetes in that it is 
unaccompanied by a period of hyperinsulinemia and is characterized by early – 
as opposed to late – onset of hyperglycemia.  
 
 
 
Figure 1.  Pathophysiologic mechanisms of diabetic cardiomyopathy. AGEs advanced 
glycation end-products, FFA free fatty acids, GLUT glucose transporter, NO nitric 
oxide, PDH pyruvate dehydrogenase, PKC protein kinase C, PPAR-a peroxisome 
proliferator–activated receptor-a, ROS reactive oxygen species, TG triglycerides, 
VEGF vascular endothelial growth factor. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 9 
 
Hyperglicemia 
Hyperglicemia represents one of the most important triggers of metabolic 
changes in diabetes [5]. In the absence of diabetes, approximately equivalent 
proportions of energy required for cardiac contractility come from glucose 
metabolism and free fatty acids (FFA), whereas in diabetes, myocardial glucose 
use is significantly reduced, with a shift in energy production toward FFA β-
oxidation [6].  
The reduction in glucose use in the diabetic myocardium results from 
depleted glucose transporter proteins, glucose transporter-1 (GLUT-1) and 
GLUT-4. In addition, a second mechanism of reduced glucose oxidation is via 
the inhibitory effect of fatty acid oxidation on pyruvate dehydrogenase complex 
due to high circulating free fatty acids, this induces an impairment in the 
myocardial energy production and leads to the accumulation of glycolitic 
intermediates and ceramide, enhancing apoptosis [7,8]. Also, peroxisome 
proliferators-activator receptor-α (PPAR-α)-enhanced activity in diabetes 
mellitus (DM) increases the expression of pyruvate dehydrogenase kinase 4 
and other genes involved in the regulation of cellular FFA uptake and β-
oxidation and also reduces glucose oxidation.  
Furthermore, high levels of FFA are believed to be one of the major 
contributing factor in the pathogenesis of diabetes. Elevation of circulating FFAs 
is caused by enhanced adipose tissue lipolysis, and increased tissue FFAs are 
caused by the hydrolysis of augmented myocardial triglyceride stores. They 
enhance peripheral insuline resistance and trigger cell death. Moreover, in 
addition to the FFA induced inhibition of glucose oxidation, high circulating and 
cellular FFA levels may result in intracellular accumulation of potentially toxic 
intermediates of FFA (lipotoxicity), besides the abnormally high oxygen 
requirements during FFA metabolism. All these changes lead to severe 
morphological changes [9, 10, 11] and impaired myocardial performance [12, 
13, 14].  
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Oxidative stress: reactive oxygen species (ROS)  
Under physiological conditions, reactive oxygen species (ROS), such as 
superoxide radical, hydroxyl radical, and hydrogen peroxide (H2O2) are 
continuously produced in many cells, but ROS levels are regulated by a number 
of enzymes and physiological antioxidants, such as superoxide dismutase, 
glutathione peroxidase, catalase, and thioredoxin. 
However, when the production of ROS outweighs their degradation by 
antioxidant defences, oxidative stress will develop and impose a harmful effect 
on the functional integrity of biological tissues.  
Large experimental and clinical studies have shown that the generation 
of ROS is increased in both types of diabetes and that the onset of diabetes and 
its complications, including diabetic cardiomyopathy, are associated with 
oxidative stress [15, 16]. It has been postulated that hyperglycemia may 
produce ROS through the formation of advanced glycation end products (AGEs) 
[17, 18] and altered polyol pathway activity [19], and through the activation of 
NADPH oxidase via protein kinase C (PKC) [20]. The increase in ROS, closely 
related with mitochondrial damage, causes cardiac dysfunction by direct 
damage to proteins and DNA as well as by promoting apoptosis [21, 22], 
abnormalities in calcium homeostasis and endothelial dysfunction [23, 24]. Cell 
death is an important determinant of cardiac remodeling because it causes a 
loss of contractile units, compensatory hypertrophy of myocardial cells and 
reparative fibrosis [25].  
Even if it is well documented that the increase in oxidative stress plays 
an important role in the development of diabetic cardiomyopathy [26], the 
precise mechanism(s) by which ROS accumulation leads to compromised heart 
function and the effect of antioxidant therapy in diabetic subjects is largely 
unknown, although experimental data suggest that regimes targeting reduction 
of ROS or increasing antioxidant activity potentially represent novel therapeutic 
modalities for diabetic cardiomyopathy. 
 
In Figure 2 are summarized the interactions between the myocardial and 
vascular changes present in diabetic hearts and their contribution to diabetic 
cardiomyopathy and heart failure 
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Figure 2. Summary of the interactions between the myocardial and vascular changes 
present in diabetic hearts and their contribution to diabetic cardiomyopathy and heart 
failure. 
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Stem cell involvement 
Emerging evidence suggests that, not only adult cardiac cells, but also 
cardiac stem/progenitor cell (CSPC) compartments are involved in the 
pathophysiology of DCM. It has been shown that several sub-populations of 
CSPCs reside within the adult heart and possess the ability to differentiate into 
all constituent cells of cardiac tissue including cardiomyocytes, vascular smooth 
muscle, endothelial cells and fibroblasts [27, 28].  
In early phases of diabetes, the activation of CSPCs associated with 
proliferation of functionally competent and properly integrated myocytes was 
shown to represent a compensatory mechanism to counteract cell loss and to 
preserve cardiac electromechanical performance [29]. However, later phases of 
diabetes are characterized by progressive CSPCs damage and exhaustion 
associated with the loss of the physiological balance between cell death and 
regeneration, leading to overt ventricular dysfunction [30, 31] (Fig. 3).  
 
 
 
Figure 3. Oxidative DNA damage in CSPCs (A) and myocytes (B) with high nuclear 
content of 8-hydroxydeoxyguanosine (8-OH-dG).  
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Antioxidant treatment  
 
Strategies aimed at preserving both parenchymal cells and the pool of 
progenitor cells responsible for tissue homeostasis may represent an innovative 
approach for DCM prevention and treatment. 
As previously described high levels of oxidative stress trigger cellular damage 
pathways and are critically involved in cardiac stem/progenitor and parenchimal 
cell loss [32, 33].  
It follows that therapies able to reduce ROS and to enhance ROS 
scavenging systems should have a promising therapeutic efficacy.  
 
Resveratrol (RSV) 
Resveratrol (3,5,4′-trihydroxystilbene) is a non-flavonoid polyphenolic 
compound abundant in grapes, peanuts and other foods that are commonly 
consumed as part of human diet (Fig. 4). The compound was first isolated from 
the root of Polygonum cuspidatum, a plant used in traditional Chinese and 
Japanese medicine [34]. Polyphenols accumulate in plants in response to 
exogenous stress factors such as injury, fungal infections or UV irradiation [35]. 
Humans have been exposed to dietary polyphenols for millions of years, and 
have developed tolerance to this group of plant defense compounds [36, 37]. 
Starting in the 1990s and continuing to date, scientific studies have 
reported that RSV has a broad range of desiderable biological actions, in 
particular a primary impetus for research on RSV was initiated from the 
paradoxical observation that a low incidence of cardiovascular diseases may 
co-exist with a high-fat diet intake and moderate consumption of red wine [38, 
39], a phenomenon known as the French Paradox [40]. 
Besides its antioxidant, anti-apoptotic/anti-inflammatory effects, RSV was 
shown to exert several other cardioprotective actions, in both ischemic and 
diabetic rat heart [41, 42, 43]. In experimental models of diabetes, it has been 
reported that RSV administration reduces reactive oxygen species [44] and the 
incidence of cardiomyocyte death [45, 46], and improves cardiac function by 
enhancing the expression of sarcoplasmic calcium ATPase (SERCA2a) in 
cardiomyocytes, through the activation of deacetylase silent information 
regulator 2/sirtuin 1 (SIRT1) [47]. 
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 Recent data also indicate that RSV may exert beneficial effects on 
cultured human circulating endothelial progenitor cells, at least in part mediated 
by inhibited p38-phosphorylation and enhanced NO levels [48]. Finally, in rat 
models of myocardial infarction subjected to stem-cell regenerative therapy, 
pre-treatment with RSV was shown to enhance stem cell survival and 
proliferation [49]. 
 
 
 
Figure 4. RSV molecule and food sources. 
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Aim of the thesis 
 
Although RSV holds great promise in the treatment of DCM by regulating 
several target molecules that protect the myocardium and prevent morpho-
functional ventricular remodeling, the potential RSV-induced improvement in the 
number and function of adult CSPCs in diabetic hearts remains to be explored.  
In the present study we specifically addressed this issue in a rat model of 
STZ-induced diabetes, one of the most commonly used experimental model of 
type 1 diabetes particularly useful in examining the effects of hyperglycemia 
without hyperinsulinemia, associated with modest hypertriglyceridemia and 
ketosis [50].  
Following an approach from intact animal to tissue-cellular-molecular 
level, we tested the hypothesis that early administration of RSV can prevent the 
onset and development of DCM.   
 Thus, at different times after the induction of hyperglycemia, we 
evaluated the potential protective role of RSV on (i) the progenitor cell 
compartment, positively interfering with the onset and development of DCM 
phenotype, (ii) the myocardial environment and its impact on CSPC survival and 
functional properties, (iii) the changes in the relative expression of cardiac actin 
isoforms usually associated with the progression of  myocardial damage [51]. 
The functional counterpart of the above processes was also evaluated, in terms 
of hemodynamics and cardiomyocyte contractile properties.  
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The investigation was approved by the Veterinary Animal Care and Use 
Committee of the University of Parma-Italy and conforms to the National Ethical 
Guidelines of the Italian Ministry of Health (Permit number: 41/2009-B) and the 
Guide for the Care and Use of Laboratory Animals (National Institute of Health, 
Bethesda, MD,USA, revised 1996). All surgery was performed under ketamine 
chloride anesthesia, and all efforts were made to minimize suffering. 
  
Animals and housing 
The study population consisted of 143 male Wistar rats (Rattus 
norvegicus) aged 12-14 wk, weighing 300-350 g. Animals were kept in 
unisexual groups of four individuals from weaning (4wk after birth) until the 
onset of the experiments, in a temperature-controlled room at 22–24 °C, with 
the light on between 7.00 AM and 7.00 PM. The bedding of the cages consisted 
of wood shavings, and food and water were freely available.  
In 118 animals (Group D), diabetes was induced by a single intra-
peritoneal injection of streptozotocin (STZ, 60 mg/kg) while the remaining 25 
control rats (group C) were injected only with saline vehicle (0.9% NaCl). 
Glucose blood levels and body weights were measured in 2-hour-fasting 
animals, before STZ or vehicle injection, two days after injection, and then 
weekly until sacrifice.  
D animals were either untreated (n=54) or subjected to chronic 
administration of (i) low doses of trans-Resveratrol (Sigma, Milan, Italy), 
(intraperitoneal injection: 2.5 mg/Kg/day; DR groups, n=64). The treatment 
started immediately after the documented increase in glucose blood levels (2 
days after STZ injection).  
Functional measurements and sacrifice were performed 1 week (D1, 
D1R groups), 3 weeks (D3, D3R) or 8 weeks (D8, D8R) after induction of 
hyperglycemia.  
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Functional measurements 
 
Hemodynamic study 
Invasive  hemodynamic data were recorded in 83 rats (12 D1, 17 D1R, 
10 D3, 13 D3R, 8 D8, 11 D8R, and 12 C). Each rat was anaesthetized with 
ketamine chloride 40 mg/kg i.p. (Imalgene, Merial, Milano, Italy), plus 
medetomidine hydrochloride 0.15 mg/kg ip (Domitor, Pfizer Italia S.r.l., Latina, 
Italy). 
The right carotid artery was cannulated with a microtip pressure 
transducer catheter (Millar SPC-320, Millar Instruments, Houston, TX, USA) 
connected to a recording system (Power Laboratory ML 845/4 channels, 
2Biological Instruments, Besozzo, Italy) and systolic and diastolic blood 
pressures were determined. The catheter was then advanced into the left 
ventricle to measure: 1) LV systolic pressure (LVSP), 2) LV end-diastolic 
pressure (LVEDP), 3) the peak rate of rise and decline of LV pressure (±dP/dt), 
taken as indexes of myocardial mechanical efficiency, 4) isovolumic contraction 
time (IVCT: duration of isovolumic contraction), and 5) LV relaxation time 
(LVRT), computed from –dP/dt to 5 mmHg above LVEDP [52] (software 
package CHART B4.2) (Fig. 5). 
Then, the hearts of D, DR and C rats were divided in two subgroups and 
used for electrophoresis and immunoblot assay (n=3 for each group) or 
morphometric and immunohistochemical analyses (see below). 
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Figure 5. Tracing example of the left ventricular pressure recorded in one 
representative control rat in A. Enlargement of a single cardiac cycle in B and in C first 
derivative of the time function described in B. 
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Myocyte Isolation and measurement of cell mechanics  
The remaining 60 rats were used for cardiomyocyte and CSPC isolation.  
From the hearts of 8 D1, 8 D1R, 8 D3, 9 D3R, 8 D8, 6 D8R, and 13 C rats, 
individual ventricular myocytes were enzymatically isolated by collagenase 
perfusion in accordance with a procedure previously described [53].  
Briefly, the rat heart was removed and rapidly perfused at 37 °C by 
means of an aortic cannula with the following sequence of solutions: 1) a 
calcium-free solution for 5 min to remove the blood, 2) a low-calcium solution 
(0.1 mM) plus 1 mg/ml type 2 collagenase (Worthington Biochemical 
Corporation, Lakewood, NJ, USA), and 0.1 mg/ml type XIV protease (Sigma, 
Milan, Italy) for about 20 min; and 3) an enzyme-free, low-calcium solution for 5 
min. Calcium-free solution contained the following (in mM): 126 NaCl, 22 
dextrose, 5.0 MgCl2, 4.4 KCl, 20 taurine, 5 creatine, 5 Na pyruvate, 1 NaH2PO4, 
and 24 HEPES (pH = 7.4, adjusted with NaOH), and the solution was gassed 
with 100% O2. 
The LV was then minced and shaken for 10 min. The cells were filtered 
through a nylon mesh and re-suspended in low-calcium solutions for 30 min. 
Then, cells were used for measuring sarcomere shortening and calcium 
transients.  
Smears were also made, and LV cells were stained with toluidine-blue. 
For each group, 500 cells were analyzed by optical microscopy to calculate cell 
surface area (Fig. 6). 
Mechanical properties of ventricular myocytes were assessed by using 
the IonOptix fluorescence and contractility systems (IonOptix, Milton, MA, USA).  
 
 
 
 
 
 
 
 
 
Figure 6. Smeared LV cardiomyocytes stained with toluidine-blue. 
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Sarcomere length. LV myocytes were placed in a chamber mounted on 
the stage of an inverted microscope (Nikon-Eclipse TE2000-U, Nikon 
Instruments, Florence, Italy) and superfused (1 ml/min at 37 °C) with a Tyrode 
solution containing (in mM): 140 NaCl, 5.4 KCl, 1 MgCl2, 5 HEPES, 5.5 glucose, 
and 1 CaCl2 (pH 7.4, adjusted with NaOH).  
Only rod-shaped myocytes with clear edges and average sarcomere 
length ≥ 1.7 µm were selected for the analysis. All the selected myocytes did 
not show spontaneous contractions. The cells were field stimulated at a 
frequency of 1 Hz by rectangular depolarizing pulses (2 ms in duration, and 
twice diastolic threshold in intensity) by platinum electrodes placed on opposite 
sides of the chamber, connected to a MyoPacer Field Stimulator (IonOptix). The 
stimulated myocyte was displayed on a computer monitor using an IonOptix 
MyoCam camera. Load-free contraction of myocytes was measured with the 
IonOptix system, which records the sarcomere pattern to calculate the changes 
in the sarcomere spacing with a fast Fourier transform algorithm. Then, 
frequency data were converted to length. 
A total of 638 isolated ventricular myocytes were analyzed (125 from C 
hearts, 85 from D1, 80 from D3, 83 from D8, 111 from D1R, 95 from D3R and 
59 from D8R) to assess cellular mechanical properties by computing the 
following parameters: mean diastolic sarcomere length, fraction of shortening 
(FS), and maximal rates of shortening and re-lengthening (±dL/dt).  
Steady-state contraction of myocytes was achieved before data recording.  
In 30 cells of each group, Ca2+ transients were measured simultaneously 
with mechanical properties. Ca2+ transients were determined by epifluorescence 
after loading the myocytes with 10 µM fluo 3-AM (Invitrogen, Carlsbad, CA) for 
30 min. Excitation length was 480 nm, with emission collected at 535 nm using 
a X40 oil objective. Fluo 3 signals were expressed as normalized fluorescence 
(f/f0: fold increase). The time course of the fluorescence signal decay was 
described by a single exponential equation, and the time constant (Tau) was 
used as a measure of the rate of intracellular calcium clearing.  
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CSPC isolation and cell cultures  
 
CSPC-isolation 
CSPCs were enzimatically isolated from the heart of control rat hearts. 
The isolation procedure was the same as for cardiomyocytes, but ventricular 
fragments were maintained for a longer time in a collagenase+albumine 
solution at 37 °C to allow mechanical tissue dissoc iation. The solution 
containing all cells was washed several times, centrifuged at 300 rpm to remove 
cardiomyocytes, and then submitted to Percoll (Sigma, Milan, Italy) gradient to 
further enrich the fraction of small cells. The cell layer visualized at the interface 
of the desired gradient was centrifuged at 1000 rpm and cells re-suspended in 
10 ml of culture medium containing Iscove Modified Dulbecco’s Medium (IMDM, 
Sigma, Italy) supplemented with 1% Penicillin-Streptomycin (P/S, Sigma, Italy), 
1% Insulin-Transferrin-Sodium Selenite (I/T/S, Sigma, Italy), 10% Fetal Bovine 
Serum (FBS, Sigma, Italy) and 10 ng/ml Basic-Fibroblast Growth Factor (b-
FGF, Sigma, Italy) and seeded in Petri dishes (Corning, USA) placed at 37 °C-
5% CO2 for their amplification.  
Daily, microscopic observation of cultures allowed the recognition of two 
different adherent cell populations, one with mesenchymal-like and one with 
monomorphic blast-like characteristics. This latter population constitutes the so-
called Cardiac Progenitor Cells (CSPCs) which exhibits clonogenic growth and 
multipotency [54, 55]. These cells were amplified for several passages and 
cryo-preserved in aliquots in a medium composed by FBS supplemented with 
1% Dimethylsulphoxide (DMSO, Sigma, Italy). 
 
Co-cultures: CSPCs-cardiomyocytes 
In order to evaluate whether and to which extent the functional properties 
of CSPCs were affected by parenchymal cells of RSV-treated and untreated 
hearts, control CSPCs (previously expanded from passage 1 to 4) were seeded 
at a concentration of 35,000/cm2 together with ventricular cardiomyocytes (at a 
concentration of 18,000/cm2) isolated from untreated and RSV-treated D1, D3 
and D8 hearts (Fig. 7).  
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Growth (phospho-histone H3-positive CSPCs; polyclonal rabbit anti-ph-
H3, Upstate, Charlottesville, VA, USA) and survival characteristics (TUNEL 
assay) of CSPCs were analyzed after 72 hours of co-culture. 
 
 
 
 
 
 
 
 
 
 
Figure 7. Examples of cultured isolated LV myocytes (A) and control CSPCs (B). 
 
Analysis of conditioned media 
The conditioned medium from each co-culture was harvested after 72 
hours and evaluated using RayBio Rat Cytokine Antibody Array II purchased  
from RayBiotech (Norgross, GA, USA). This assay can simultaneously detect 
the expression level of different cytokines with high specificity.  Briefly, after 
treating the membranes with a blocking buffer, 1 ml of conditioned medium was 
added and incubated at room temperature for 2 hours. The membranes were 
washed, and 1 ml of primary biotin-conjugated antibody was added and 
incubated at room temperature for 2 hours. Then, the membranes were 
incubated with 2 ml of horseradish peroxidase-conjugated streptavidin at room 
temperature for 1 hour and subsequently developed by using enhanced 
chemiluminescence-type solution (Immobilon Western-Millipore) and exposed 
to Kodack X-Omat AR film for an appropriate length of time (Fig. 8). The 
intensities of signals were quantified by densitometry (software for image 
capturing and analysis: ImageQuant- Molecular Dynamics). For each spot the 
net density was determined by subtracting the background gray levels. The 
density of the positive control spots were used to normalize the results from the 
different membranes.  
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Figure 8. Rat Cytokine antibody array II working procedure. 
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Cardiac anatomy and morphometry  
In 9 C, 9 D1, 14 D1R, 7 D3, 10 D3R, 5 D8 and 8 D8R rats, the abdominal 
aorta was cannulated, the heart was arrested in diastole with injection of CdCl2 
solution (100 mM), and the myocardium was retrogradely perfused with 10% 
buffered formalin solution. The left ventricular chamber was filled with fixative at 
a pressure equal to the in vivo measured systolic pressure. The heart was then 
excised and placed in formalin solution (10%) for 24 hours. 
Cardiac anatomy. The right ventricle (RV) and the left ventricle (LV) 
inclusive of the septum were separately weighed and the volume of the left 
ventricular myocardium was computed by dividing LV myocardial weight by the 
specific weight of the tissue (1.06 g/ml). LV chamber length was measured from 
the apex to the aortic valve. A 1-mm-thick transverse slice was cut from the 
mid-region of the LV and used to compute LV wall thickness and chamber 
equatorial diameter (Image Pro-plus, Media Cybernetics, Bethesda, MD, USA, 
version 7.0). The LV chamber volume was calculated according to the Dodge 
equation which equalizes the ventricular cavity to an ellipsoid [56]. The slice 
was then embedded in paraffin and five-micrometer-thick sections were cut and 
used for morphometric and immunohistochemical analyses. 
Morphometric analysis. Sections were stained with Masson’s trichrome 
and analyzed by optical microscopy (magnification 250X) in order to evaluate in 
the ventricular myocardium: (i) the volume fraction of myocytes, (ii) the volume 
fraction of interstitial and perivascular fibrosis, and (iii) the numerical density 
and average cross-sectional area of fibrotic foci. According to a procedure 
previously described [57], for each section, these analyses were performed in 
60 adjacent fields from sub-endocardium, mid-myocardium and sub-epicardium. 
The measurements were obtained with the aid of a grid defining a tissue area of 
0.160 mm2 and containing 42 sampling points each covering an area of 0.0038 
mm2. 
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Immunohistochemistry  
Atrial and LV sections were analyzed to estimate (i) the percentage of 
apoptotic cells (TUNEL assay), (ii) the numerical density of cells expressing c-
kit, the receptor for Stem Cell Factor (rabbit polyclonal anti-c-kit antibody, 
Santacruz Biotecnology, Santa Cruz, CA, USA), (iii) the arteriolar and capillary 
density (mouse monoclonal anti-alpha-smooth muscle actin antibody and rabbit 
polyclonal anti-vW factor, Dako, Glostrup, Denmark); (iv) the relative expression 
of alpha cardiac isoforms [58] by using specific antibodies against α-smooth 
muscle actin (α-SMA), α-cardiac actin (α-CA) and α-skeletal actin (α-SKA). All 
these antibodies have been developed and characterized in the Dept. of 
Pathology and Immunology, University of Geneva, Switzerland [59, 60, 61] 
  
Electrophoresis and immunoblot assay 
In 3 rats for each group, the hearts were excised, and the left and right 
ventricles were weighed and immediately frozen at -80 °C. Western blot assay 
was used to assess the expression levels of high-mobility group box-1 protein 
(HMGB-1) as an index of activation of pro-inflammatory signal cascades in 
ventricular myocardial tissue.  
The left ventricular tissue was mechanically fragmented in liquid nitrogen, 
homogenized in Sample Buffer (62.5 mM Tris-HCl, pH 6.8, 2% sodium dodecyl 
sulfate (SDS), 10% glycerol, 50 mM DTT, 0.01% bromophenol blue) and boiled 
for 5 min. For each animal, 50 µg of proteins were separated on 10% 
polyacrylamide gels and electroblotted on nitrocellulose membranes (Protran, 
Schleicher & Schuell, Dassel, Germany). Membranes were blocked with 5% 
milk in TBS-T (Tris-Buffered Saline Tween-20) and were incubated overnight at 
4 °C with the primary antibody (anti-HMGB1 rabbit p olyclonal antibody, Abcam, 
Cambridge, UK). After washing the membranes, a second incubation was 
performed for one hour at room temperature with peroxidase conjugated affinity 
purified goat anti-rabbit secondary antibody (Jackson Immunoresearch 
Laboratories, West Grove, PA). Peroxidase activity was developed using the 
ECL Western blotting system (Amersham, Rahn AG, Zürich, Switzerland), 
according to the instructions of the manufacturer. To determine the expression 
levels of HMGB-1, blots were scanned and the intensity of the band was 
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quantified by means of the ImageJ Program (NIH, Bethesda, MD, USA). Actin 
(anti-actin rabbit polyclonal antibody, Sigma) was used as the loading control. 
 
Statistical analysis 
Power analysis has been performed to evaluate the research design and 
minimize Type II errors and sample size. Preliminary hemodynamic data 
obtained in a pilot study have been used. The ANOVA statistical test was used 
for computing the F value, the significance level, the effect size and the non-
centrality parameter (PASW Statistics 18). Then, a-priori power analysis was 
used (G*Power Version 3.1.2; Franz Faul, Kiel University, Germany) by setting 
α=0.01 and β=0.05 (power 1-β=0.95) in accordance with the suggestion of 
Cohen [62], to estimate total sample size and the number of measurements 
required for each group. Statistics of variables included mean±standard error 
(SE), Multifactorial analysis of variance (1 way ANOVA followed by Bonferroni’s 
post-hoc test or Dunnett’s test when appropriate).  Statistical significance was 
set at p<0.05. 
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Glucose blood levels and body weight 
At the beginning of the experimental protocol, glucose blood levels and 
body weight ranged respectively between 102-109 mg/dl and 301-445 g, in the 
entire rat population. In D animals, after STZ injection, glucose blood levels 
were higher than those measured in C group, at every time points of 
observation (Table 1). In addition, body weight decreased by 15% during the 
first week of hyperglycemia to remain essentially constant until 8 weeks (Table 
1). RSV treatment did not significantly affect both glucose blood levels and body 
weight (Table 1). 
 
 
         Body weight and glucose blood levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Values are mean ± SE of body weight (BW) and glucose blood levels 
measured in control (C), diabetic (D) and RSV-treated diabetic rats (DR), at 1-3-8 
weeks after STZ or vehicle injection. * p < 0.01 significant differences vs. C animals. 
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Hemodynamics 
Heart rate measured under anesthesia was similar in all experimental 
groups (heart rate ranging from 195 and 220 beats/minute, in the different 
groups). In comparison with C rats, all diabetic groups exhibited significantly 
lower values of systolic LV pressure (range: 103-112 mmHg vs. 133 mmHg 
measured in C) (Fig. 9) while end-diastolic pressure was unchanged (range: 5-9 
mmHg). Marked signs of systolic and diastolic ventricular dysfunction developed 
after 8 weeks of diabetes, including a significant reduction in ±dP/dt (Fig. 10 A-
B), associated with a prolongation of both isovolumic contraction time (IVCT) 
and relaxation time (LVRT) (Fig. 10 C-D).  
In D8R group, RSV treatment abolished the negative impact of diabetes 
on LV hemodynamics and all parameters reached control values with the 
exception of the rate of pressure decline during relaxation (-dP/dt) (Fig. 10 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Hemodynamic measurements 
Mean values ± SE of left ventricular systolic pressure (LVSP). * p < 0.01: significant 
differences vs. C. 
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Figure 10. Hemodynamic measurements 
Mean values ± SE of: A) maximum rate of ventricular pressure rise (+dP/dt), B) 
maximum rate of ventricular pressure reduction (-dP/dt), C) isovolumic contraction time 
(IVCT), and D) LV relaxation time (LVRT), measured in control rats (C) and untreated 
or RSV-treated diabetic rats after 1 (D1, D1R), 3 (D3, D3R) and 8 (D8, D8R) weeks of 
hyperglycemia. * p < 0.01: significant differences vs. C; # p < 0.05: significant 
differences between D8 and D8R. 
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Cell mechanics and calcium transients 
Globally, 638 isolated ventricular myocytes were used for cell mechanics 
(125 from C hearts, 85 from D1, 80 from D3, 83 from D8, 111 from D1R, 95 
from D3R and 59 from D8R). In 30 cells of each experimental group, calcium 
transients were simultaneously recorded. The average diastolic sarcomere 
length was comparable in all groups (average sarcomere length equal to 
1.71±0.001 µm).  
In accordance with the in vivo recorded hemodynamic data, the 
mechanical properties of ventricular myocytes from D1 and D3 diabetic hearts 
were globally preserved (Fig. 11 B-D), except for the lower rate of intracellular 
calcium clearing (Tau) in D3 (Fig. 12 B). Conversely, a definite worsening of cell 
mechanics occurred in D8 (Fig. 11 A-D). In comparison with C cells, D8 
cardiomyocytes exhibited a reduced fraction of shortening associated with a 
significant decrease in the maximal rate of shortening (-dL/dt) and relengthening 
(+dL/dt) (p<0.01; Fig. 11 B-D). The impaired contractility in D8 cells was 
accompanied by a significant decrease in calcium transient amplitude (f/f0) (-
15%, p<0.01; Fig. 12 A) and a prolonged Tau (+50%, p<0.01; Fig. 12 B). The 
progressive impairment of cardiomyocyte contractile efficiency produced by 
diabetes was partially improved by RSV treatment as shown by the recovery of 
fraction of shortening (Fig. 11 B) and f/f0 (Fig. 12 A).  
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Figure 11. Cell mechanics 
A) Representative examples of sarcomere shortening and corresponding calcium 
transients (normalized tracings: fold increase) recorded from C and D8 ventricular 
myocytes. In bar graphs, the mean values ± SE of: B) sarcomere fraction of shortening, 
C) maximal rate of shortening (-dL/dt), D) maximal rate of relengthening (+dL/dt), 
measured in control myocytes (C), and untreated or RSV-treated diabetic cells (D and 
DR, respectively), after 1, 3 and 8  weeks of hyperglycemia.  
 * p < 0.01: significant differences vs. C; # p < 0.05: significant differences between D8 
and D8R. 
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Figure 12. Intracellular calcium transients 
In bar graphs, the mean values ± SE of: A) calcium transient amplitude expressed as 
peak fluorescence normalized to baseline fluorescence (f/f0) and B) time constant of 
the intracellular calcium decay (Tau), measured in control myocytes (C), and untreated 
or RSV-treated diabetic cells (D and DR, respectively), after 1, 3 and 8  weeks of 
hyperglycemia.  
 * p < 0.01: significant differences vs. C; # p < 0.05: significant differences between D8 
and D8R. 
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Effects of diabetes and RSV on cardiac anatomy and myocardial tissue 
Diabetes induced a marked loss of left ventricular mass in D1, D3 and D8 
untreated hearts (p<0.05; Fig. 13 A), in the absence of significant changes in 
individual cardiomyocyte size (average cardiomyocyte surface area: 
approximately 1,400 µm2, data not shown). A significant dilation of LV chamber 
was observed only after 8 weeks of diabetes (Fig. 13 B) leading to a marked 
reduction in mass-to-chamber volume ratio in D8 group (Fig. 13 C). These 
unfavorable anatomical changes produced by diabetes were reversed by RSV 
administration (Fig. 13 A-C). 
 The total amount of collagen accumulation was negligible and similar to 
control ventricles in RSV-treated and untreated diabetic hearts during the first 3 
weeks of hyperglycemia. In D8 group, although myocardial damage was still 
limited, the total amount of fibrosis in the myocardium was significantly 
increased in comparison with C (Fig. 14 A). Perivascular fibrosis was observed 
in association with small foci of reparative fibrosis characterized by 
inflammatory cellular infiltrates (Fig. 14 B-C), more evident in the mid-
myocardium. The activation of pro-inflammatory signal cascades was confirmed 
by the significant increase in HMGB-1 expression in D8 group, as revealed by 
Western blotting assay (Fig. 15). Cardiac damage and inflammation signals 
were completely prevented by RSV administration (Fig. 14 A, 15). 
Significantly lower values of α-SKA expression were also detected in 
diabetic cardiomyocytes, after 3 and 8 weeks of hyperglycemia (-50% on 
average in both groups vs. C; Fig. 16 A-B). This reduction was counteracted by 
RSV-treatment in D3R group (Fig. 16 A-B) while the effect of RSV was less 
evident at the later time point (D8R group). 
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Figure 13. Cardiac anatomy and tissue morphometry 
In A-C graphs the mean values ± SE of the left ventricular (LV) geometrical properties 
measured in the different experimental groups: A) LV mass, B) LV chamber volume, 
and C) LV mass to chamber volume ratio.  
* p < 0.05: significant differences vs. C; # p < 0.05: significant differences vs. the 
corresponding RSV-treated group. 
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Figure 14. Cardiac anatomy and tissue morphometry 
In A) mean values ± SE of the volume fraction of fibrosis morphometrically determined 
in D8 and D8R groups. B-C: sections of LV mid-myocardium stained with Masson’s 
trichrome showing in greenish blue the fibrotic tissue in a D8 rat heart. B: accumulation 
of collagen in perivascular space. C: focal damage characterized by the presence of 
collagen and inflammatory cell infiltrate. Scale bars = 100 µm. 
 * p < 0.05: significant differences vs. C; # p < 0.05: significant differences vs. the 
corresponding RSV-treated group. 
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Figure 15. HMGB-1 expression in left ventricular myocardium 
Expression levels of high mobility group box-1 protein (HMGB-1) in left ventricular 
myocardium. OD: optical density. Data are reported as mean ± SE. 
 * p < 0.01: significant differences vs. C; # p < 0.05: significant differences vs. the 
corresponding RSV-treated group. 
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Figure 16. Alpha-SKA expression in left ventricular myocardium  
A) Expression levels of α-SKA in left ventricular myocardial tissue. Data are reported as 
mean ± SE. * p < 0.01: significant differences vs. C; # p < 0.05: significant differences 
vs. the corresponding RSV-treated group.  
B) Sections of D3 (upper panels) and D3R (lower panels) LV myocardium stained with 
anti α-SKA. Black squares inscribe an area shown at higher magnification in the 
corresponding adjacent panels. Scale bar = 100 µm. 
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Effects of RSV on diabetes-induced cardiomyocyte and endothelial cell 
apoptosis 
To determine ongoing apoptotic cell death, tissue sections of the LV 
myocardium were subjected to the TUNEL assay. In comparison with control 
hearts, the percentage of apoptotic cardiomyocytes increased with diabetes at 
all time points of observation (Fig. 17 A) while apoptosis in endothelial cells 
increased from 3 to 8 weeks (Fig. 17 B). Overall, RSV treatment was able to 
reduce by 65% to 85% the incidence of apoptotic cell death (Fig. 17 A-B) 
although, after 8 weeks of diabetes, a marked protective effect was maintained 
only on endothelial cells (Fig. 17 B).  
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Figure 17. Effects of diabetes and RSV on myocardial cell apoptosis 
Bar graphs illustrate the percentage of apoptotic cardiomyocytes (A) and endothelial 
cells (B). Data are expressed as mean values ± SE. 
 * p < 0.01: significant differences vs. C; # p < 0.05: significant differences vs. the 
corresponding RSV-treated group. 
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Effects of diabetes and RSV treatment on CSPCs  
 
Tissue analysis 
To evaluate the effects of diabetes and RSV treatment on the numerical 
density and tissue distribution of CSPCs, sections of the atria and LV from all 
experimental groups were immunostained for the detection of c-kit, the receptor 
of Stem Cell Factor, representing the most preserved stem cell antigen among 
different tissues of different species [63].  
As expected, the quantitative analysis documented that in control hearts 
the number of c-kit-positive  CSPCs was 2.5 fold higher in the atria with respect 
to the LV supporting the notion of preferential sites of accumulation of cardiac 
primitive cells [28]. Diabetes significantly reduced the density of CSPCs in the 
atrial appendages at all time points (Fig. 18 A). Conversely, the deleterious 
effect of diabetes on left ventricular CSPCs was detected only after 8 weeks of 
hyperglycemia (Fig. 18 B). RSV administration significantly attenuated the early 
and late dramatic depletion of CSPCs from the atrial sites of storage (Fig. 18 A), 
although was not able to counteract the late diabetes-induced loss of progenitor 
cell compartments in the working left ventricle (Fig. 18 B).  
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Figure 18. Effects of diabetes and RSV on CSPC number 
Bar graphs illustrate the numerical density of atrial (A) and ventricular (A) c-kit+ 
CSPCs. OD: optical density. Data are expressed as mean values ± SE.  
* p < 0.01: significant differences vs. C; # p < 0.05: significant differences vs. the 
corresponding RSV-treated group. 
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In vitro analysis 
It is well established that, especially at the level of niches, stem cell 
function is tightly regulated by environmental factors [29]. Thus, we determined 
in vitro whether the negative impact of diabetes and the protective action of 
RSV on CSPCs could be attributed to changes in myocardial environment. 
Specifically, the effect of diabetic cardiomyocytes, isolated from RSV-treated 
and untreated diabetic hearts, on the magnitude of CSPCs apoptotic death 
(TUNEL) and proliferation (Ph-H3) was analyzed.  
CSPCs co-cultured with D1, D3 or D8 diabetic cardiomyocytes exhibited 
a higher rate of death associated with a lower proliferation capacity leading to 
an increased death-to-proliferation ratio, in comparison with CSPCs co-cultured 
with RSV-treated cardiomyocytes, at all time points of observation (Fig. 19 A). 
However, no linear relationship with the duration of diabetes was observed on 
this parameter. These in vitro observations suggest that the diabetic “milieu” 
impairs CSPC turnover which can be reversed by RSV. To investigate this 
phenomenon, we determined the relative concentrations of several cytokines in 
the media harvested from each co-culture condition.  
The presence of cardiomyocytes isolated from D1 and D3 untreated 
diabetic hearts mainly resulted in a higher concentration of the monocyte 
chemotactic protein-1 (MCP-1) as compared with the conditioned media 
collected from co-cultures containing RSV-treated cardiomyocytes (D1R, D3R; 
Fig. 19 B). These data suggest that the inflammatory and pro-apoptotic bulk 
produced by diabetes can be attenuated by chronic RSV administration. 
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Figure 19. Co-cultures of CSPCs and cardiomyocytes 
A: death to proliferation ratio of CSPCs co-cultured with untreated or RSV treated 
diabetic cardiomyocytes; B: concentration of the pro-inflammatory cytokine monocyte 
chemotactic protein-1 (MCP-1) in media harvested from co-cultures at different 
experimental time points. OD: optical density. Data are expressed as mean values ± 
SE. # p < 0.05: significant differences vs. co-cultures containing RSV-treated myocytes. 
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Diabetic cardiomyopathy refers to a distinct primary disease process 
which develops secondary to a metabolic insult and affects the myocardium 
causing a wide range of structural alterations and diastolic and systolic 
dysfunction or a combination of these, ultimately leading to heart failure. The 
appearance of diabetes is the factor which induces changes at the cellular level 
including chronic loss of myocytes  and vascular cells with a decrease in muscle 
mass, chamber dilation and altered extracellular matrix, with consequential 
structural and functional abnormalities. 
Accumulating evidence supports the concept that a “cardiac stem cell 
compartment disease” plays an important role in the pathophysiology of diabetic 
cardiomyopathy [30]. In the diabetic heart, enhanced oxidative stress and 
inflammation induces an imbalance between cell death and cell regeneration.  
The death of mature myocytes, smooth muscle cells, and endothelial 
cells is the initiating factor but the progression of the diabetic cardiomyopathy is 
mediated by premature cellular aging and CSPCs’ death. The loss of CSPCs 
favors cellular senescence and may promote a shift in the pattern of cell death 
from apoptosis to necrosis within the myocardium. Accumulation of old cells and 
cell necrosis alter the orderly organization of myocardial structure, depressing 
cardiac performance. Cellular senescence and attrition of the pool of 
functionally competent CSPCs lead to an insufficient replacement of old, dying 
cells and the acquisition of the heart senescent phenotype. Therefore, in the 
diabetic cardiomyopathy the cardiac stem/progenitor cell compartments 
participate in the pathophysiology of DCM favoring its onset and its progression 
towards heart failure [64]. Thus, the preservation of CSPC compartment can 
contribute to counteract the negative impact of diabetes on the myocardium.  
In the present study, we show that early treatment of diabetic rats with 
the natural polyphenolic compound Resveratrol, in addition to the protective 
effect on mature myocardial tissue, improves “myocardial diabetic milieu” and 
positively interferes with CSPC survival and functional properties, resulting in a 
decreased ventricular remodeling as compared with untreated animals. The 
functional counterpart of these effects is the recovery of cardiac hemodynamics 
associated with an improvement of cardiomyocyte mechanical properties. 
 Despite several experimental studies suggesting that antioxidants reduce 
diabetic cardiovascular complications, results from clinical trials have been 
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disappointing [65, 66] probably because traditional antioxidants have a 
scavenging action on already formed ROS but limited effects on their 
intracellular production [65].  
Here, we tested the hypothesis that early administration of RSV can be 
efficient in preventing diabetic cardiomyopathy. In comparison with conventional 
antioxidant compounds, RSV holds great promise in the treatment of 
cardiovascular complications of diabetes due to its well known effects on 
several target molecules resulting in reduced inflammation and intracellular 
ROS production, inhibiting both mitochondrial ROS production and permeability 
transition thus protecting the key intracellular organelle against the oxidative 
stress [67]. RSV was also shown to (i) decrease the rate of apoptotic cell death, 
(ii) increase cellular expression of survival proteins, and (iii) enhance stem cell 
survival and cardiac regeneration in ischemic heart [41, 68-72]. 
RSV, as other natural polyphenolic compounds, at low doses promotes 
antioxidant effects and induces survival signals resulting in cardioprotection.     
The protective role of RSV treatment was documented by the improved 
post-ischemic ventricular function and reduced myocardial infarct size and 
apoptotic cardiomyocytes and further supported by the generation of survival 
signals as evidenced by increased phosphorylation of Akt and activation of Bcl-
2 [73]. On the contrary, at higher doses (>5 mg/kg/die), RSV has detrimental 
cellular effects with a pro-oxidant role followed by cell damage, p-Akt down-
regulation and apoptosis [74]. Thus, we performed preliminary experiments in 
normal and diabetic animals in order to determine the best dose able to produce 
cardioprotection without eliciting toxic effects. The best suitable dose was fixed 
at 2.5 mg/Kg/day, delivered by intra-peritoneal injection, in accordance with 
data previously reported [73].   
Under physiological conditions, reactive oxygen species (ROS), such as 
superoxide radical, hydroxyl radical, and hydrogen peroxide (H2O2) are 
continuosly produced in many cells, but ROS levels are regulated by a number 
of enzymes and physiological antioxidants, such as superoxide dismutase, 
glutathione peroxidase, catalase, and thioredoxin. However when the 
production of ROS becomes excessive, oxidative stress will develop and 
impose a harmful effect on the functional integrity of biological tissues. The 
generation of ROS is increased in both types of diabetes leading to cell 
dysfunction and apoptosis [50, 64, 75]. Moreover it has been postulated that 
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hyperglycemia, a key clinical manifestation of diabetes, affects several other 
mechanisms leading to the generation of advanced glycation end-products 
(AGEs) and activation of diacylglycerol (DAG)-protein kinase C (PKC), resulting 
in chronic inflammation [65, 76]. This unfavorable tissue environment, besides 
inducing myocyte/endothelial cell damage, can impair mobilization, survival and 
proliferation of CSPCs. In accordance with previous reports [29, 30], we found a 
progressive reduction in CSPC density both in atrial storage and ventricular 
myocardial tissue of diabetic rats, partially reverted by RSV administration. The 
critical role played by the adverse tissue environment on CSPC survival and 
proliferation was also supported by data obtained in the co-cultures of healthy 
CSPCs and cardiomyocytes isolated from diabetic rats.   
Co-culture conditioned media showed a high concentration of the pro-
inflammatory cytokine monocyte chemotactic protein-1 (MCP-1). It has been 
recently shown [77] that hyperglicemia induces the expression of MCP-1 and 
MCP-1 induces a novel zinc-finger protein termed MCP-1-induced protein 
(MCPIP) leading to oxidative stress via iNOS or NADPH oxidase. Oxidative 
stress results in increased endoplasmic reticulum stress, autophagy and 
cardiomyocyte death, thus playing a critical role in the pathophysiological 
progression of diabetic cardiomyopathy [77].  
Systemic RSV treatment resulted in a reduced activation of pro-
inflammatory pathways, as indicated by the lower levels of MCP-1 in the co-
culture supernatant. A reduced tissue inflammation was also confirmed by the 
decreased inflammatory cell infiltration and lower expression of HMGB-1 in the 
ventricular myocardium, after 8 weeks of diabetes. HMGB-1, besides its well 
known nuclear function in transcription regulation, modifying the structure of 
DNA and stabilizing nucleosomes [78, 79], possesses an extracellular role as 
pro-inflammatory cytokine [80].  
HMGB-1 can be secreted from cells in two ways, either passively or 
actively and can play a role as an initiator of inflammation through its passive 
release from necrotic cells or as a late promoter through its active secretion by 
activated immune cells such as macrophages and monocytes [81, 82]. The 
decrease in HMGB-1 expression in D8R is supposedly due to the reduction of 
both cardiac cell death and recruitment of inflammatory cells following RSV 
administration. Oxidative stress and tissue inflammation represent important 
factors leading to lesions of small coronary arteries and appearance of 
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perivascular/interstitial fibrosis occurring in diabetic patients and in experimental 
models of diabetes [64]. The antioxidant effect of RSV associated with the 
decrease in the pro-inflammatory “milieu” may account for the preservation of 
ventricular mass and the decreased fibrotic damage observed in treated hearts, 
resulting in attenuation of cardiac remodeling and improved myocardial function.  
Our results also indicate that diabetes affects the expression of α-SKA in 
ventricular cardiomyocytes. During adult life, α-CA is the major actin isoform 
present and is uniformly expressed in myofibrils. On the contrary the expression 
of α-SKA is low and the distribution appears focal and represents about 5% of 
the total actin [51]. Previous studies showed that a higher α-SKA content is 
associated with faster heart dynamics [83] and may constitute a compensation 
mechanism to maintain cross-bridge turnover rate and achieve a high degree of 
myocardial contractility in pressure-overload cardiac hypertrophy [57]. Here, we 
found a significant reduction in α-SKA levels after 3 and 8 weeks of 
hyperglycemia while RSV treatment produced a recovery of α-SKA expression.  
Although this effect was much more evident after 3 weeks of diabetes and 
decreased with time, the early increment in α-SKA levels might contribute to 
maintain a proper answer to increased workload with a concurrent recovery of 
hemodynamic performance and cardiomyocyte mechanical properties during 
contraction, as observed at 8 weeks of diabetes.  
Our results support the assumption that RSV treatment preserves the 
numerical density and functional abilities of both mature cardiac cells and atrial 
CSPC storage, improves cardiac microenvironment and reduces unfavorable 
ventricular remodeling, thus leading to a marked recovery of ventricular function 
which was almost complete at the organ level (hemodynamics) but only partial 
at the cellular level. It is conceivable that combining RSV administration with 
traditional therapies, reducing metabolic derangements and glucose blood 
levels, and strategies aimed at enhancing RSV bioavailability [84, 85] can 
increase and prolong the positive effects of the compound. In conclusion, our 
findings indicate that RSV administration can constitute an adjuvant therapeutic 
option in the prevention and treatment of DCM opening new perspectives for 
pharmaceutical interventions in degenerative heart diseases, based on natural 
polyphenolic compounds.  
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Future perspectives  
 
Large number of scientific studies have reported that Resveratrol has a 
broad range of desiderable biological actions with beneficial potentials for 
human health, which include anti-oxidant, anti-inflammatory, cardio-protective 
and anti-tumor activities, supporting the idea that this dietary chemical may be a 
useful protective agent. 
In the present work we demonstrated that RSV holds great promise in 
the prevention and treatment of DCM by regulating several target molecules 
that preserve the myocardium and prevent ventricular remodelling. However it is 
of fundamental imortance to evaluate the molecular mechanisms underlying the 
short-term as well as the long-term effects of this compound on the electro-
mechanical properties of diabetic myocardial tissue. 
This is an important point to be explored by considering that global heart 
function strictly depends on the unique three-dimensional myocardial fibre 
architecture and the complex interplay of intrinsic mechanisms which regulate 
the sequential rise and fall of cytosolic Ca2+.  
For this reason future studies will be focused on the evaluation of early 
RSV treatment on several target molecules which are involved in the excitation-
contraction coupling with major attention on: 1) L-type Ca2+ channels 
responsible for Ca2+ entry during membrane depolarization, 2) ryanodine 
receptors which allow calcium-induced calcium release from the sarcoplasmic 
reticulum, 3) Troponin C, the protein subunit binding cytosolic Ca2+, critical first 
step that triggers actin-myosin interaction, 4) SR Ca2+ ATPase (SERCA2a) as 
the major mechanism involved in cytosolic calcium clearing, and 5) 
Phospholamban and SIRT1, as key proteins regulating SERCA2 activity and 
expression levels. In addition, the RSV effects on Connexin-43 expression will 
be determined, by considering that cardiac electromechanical performance is 
also based on a proper intercellular communication and impulse propagation via 
gap-junctions [86, 87] whose spatial distribution and biophysical properties are 
important determinants of the conduction velocity and three-dimensional pattern 
of electrical activation. 
Another important field that has to be explored is the bioavailability of 
Resveratrol which is modest, limiting the in vivo biological effect of the 
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compound and representing a barrier for the development of therapeutic 
applications. For this reason an increasing number of recent studies have 
aimed at designing novel resveratrol formulations to overcome its poor 
solubility, limited stability, high metablization and weak bioavailability.  
Therefore the future for efficient resveratrol delivery lies in the 
development of innovative strategies able to overcome each of the 
physicochemical, pharmacokinetic and metabolic limitations that characterize 
the therapeutic use of this compound. 
 
Bibliography 
 
 54 
 
Bibliography 
 
1. Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P. 
Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc 
Diabetol 2003; 2:1 
 
2. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of 
coronary artery disease? Diabetes Care 1995; 18:708-14 
 
3.  Spector KS. Diabetic cardiomyopathy. Clin Cardiol 1998; 21:885-7 
 
4. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. 
New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J 
Cardiol 1972; 30(6):595–602 
 
5. Chatham JC, Seymour AM. Cardiac carbohydrate metabolism in zucker 
diabetic fatty rats. Cardiovasc Res 2002; 55(1):104–112 
 
6. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: 
implications for diabetic cardiomyopathy. J Mol Cell Cardiol 1995; 27(1):169–
179 
 
7. Eckel J, Reinauer H. Insulin action on glucose transport in isolated cardiac 
myocytes: signalling pathways and diabetes induced alterations. Biochem Soc 
Trans 1990; 18(6):1125–1127 
 
8. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in 
substrate metabolism and effects of excess fatty acids in reperfused 
myocardium. Circ Res 1988; 62(3):535–542 
 
9. Nakayama H, Morozumi T, Nanto S, Shimonagata T, Ohara T, Takano Y, 
Kotani J, Watanabe T, Fujita M, Nishio M, Kusuoka H, Hori M, Nagata S. 
Abnormal myocardial free fatty acid utilization deteriorates with morphological 
changes in the hypertensive heart. Jpn Circ J 2001; 65(9):783 787 
 
10. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic 
cardiomyopathy. Mol Cell Biochem 1998; 180(1–2):53–57 
 
11. Yazaki Y, Isobe M, Takahashi W, Kitabayashi H, Nishiyama O, Sekiguchi M, 
Takemura T. Assessment of myocardial fatty acid metabolic abnormalities in 
patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: 
correlation with clinicopathological findings and clinical course. Heart 1999; 
81(2):153–159 
 
12. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, Tsuji T, 
Kohzuki H, Suga H, Taniguchi S, Takaki M. Left ventricular diastolic dysfunction 
in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 2002; 
282(1):H138–H148 
 
13. Malhotra A, Reich D, Nakouzi A, Sanghi V, Geenen DL, Buttrick PM. 
Experimental diabetes is associated with functional activation of protein kinase 
Bibliography 
 
 55 
c epsilon and phosphorylation of troponin i in the heart, which are prevented by 
angiotensin II receptor blockade. Circ Res 1997; 81(6):1027–1033 
 
14. Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Myocardial 
mechanical and myosin isoenzyme alterations in streptozotocin-diabetic rats. 
Jpn Heart J 1988; 29(4):455–463 
 
15. Marra G, Cotroneo P, Pitocco D, Di Leo MA, Ruotolo V, Caputo S, Giardina 
B, Ghirlanda G, Santini SA. Early increase of oxidative stress and reduced 
antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for 
gender difference. Diabetes Care 2002; 25:370-5 
 
16. Penckofer S, Schwertz D, Florczak K. Oxidative stress and cardiovascular 
disease in type 2 diabetes: the role of antioxidants and prooxidants. J 
Cardiovasc Nurs 2002; 16:68-85 
 
17. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early 
glycation products: a mechanism for accelerated atherogenesis in diabetes. 
Biochem Biophys Res Commun 1990; 173:932-9 
 
18. Baynes JW. Role of oxidative stress in development of complications in 
diabetes. Diabetes 1991; 40:405-12 
 
19. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, 
Nyengaard JR, van den Enden M, Kilo C, Tilton RG. Hyperglycemic 
pseudohypoxia and diabetic complications. Diabetes 1993; 42:801-13 
 
20. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, 
Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H. Protein kinase C 
dependent increase in reactive oxygen species (ROS) production in vascular 
tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 
14:S227-32 
 
21. Alici B, Gümüstas MK, Ozkara H, Akkus E, Demirel G, Yencilek F, Hattat H. 
Apoptosis in the erectile tissues of diabetic and healthy rats. BJU Int 2000; 
85:326-9 
 
22. Cai L, Chen S, Evans T, Deng DX, Mukherjee K, Chakrabarti S. Apoptotic 
germ-cell death and testicular damage in experimental diabetes: prevention by 
endothelin antagonism. Urol Res 2000; 28:342-7 
 
23. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, 
mechanisms, and therapeutic implications. Endocr Rev 2004; 25:543-67 
  
24. Li X, Xu Z, Li S, Rozanski GJ. Redox regulation of Ito remodelling in diabetic 
rat heart. Am J Physiol Heart Circ Physiol 2005; 288:H1417-24 
 
25.  Kang YJ. Molecular and cellular mechanisms of cardiotoxicity. Environ 
Health Perspect 2001; 109 (Suppl 1):27-34 
 
Bibliography 
 
 56 
26. Tomita M, Mukae S, Geshi E, Umetsu K, Nakatani M, Katagiri T. 
Mitochondrial respiratory impairment in streptozotocin-induced diabetic rat 
heart. Jpn Circ J 1996; 60:673-82 
 
27. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, 
Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, 
Anversa P. Adult cardiac stem cells are multipotent and support myocardial 
regeneration. Cell. 2003; 114:763-776 
 
28. Madonna R, Rokosh G, De Caterina R, Bolli R. Hepatocyte growth 
factor/Met gene transfer in cardiac stem cells--potential for cardiac repair. Basic 
Res Cardiol. 2010; 105:443-452. 
 
29. Stilli D, Lagrasta C, Berni R, Bocchi L, Savi M, Delucchi F, Graiani G, 
Monica M, Maestri R, Baruffi S, Rossi S, Macchi E, Musso E, Quaini F. 
Preservation of ventricular performance at early stages of diabetic 
cardiomyopathy involves changes in myocyte size, number and intercellular 
coupling. Basic Res Cardiol 2007; 102:488-499 
 
30. Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin-Iruegas ME, 
Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Lüscher TF, Pelicci PG, 
Anversa P, Leri A, Kajstura J. Diabetes promotes cardiac stem cell aging and 
heart failure, which are prevented by deletion of the p66shc gene. Circ Res 
2006; 99:42-52 
 
31. Kajstura J, Urbanek K, Rota M, Bearzi C, Hosoda T, Bolli R, Anversa P, Leri 
A. Cardiac stem cells and myocardial disease. J Mol Cell Cardiol 2008; 45: 
505–513 
 
32. Pervaiz S, Taneja R, Ghaffari S. Oxidative stress regulation of stem and 
progenitor cells. Antioxid Redox Signal. 2009; 11:2777-2789 
 
33. Chen Q, Dong L, Wang L, Kang L, Xu B. Advanced glycation end products 
impair function of late endothelial progenitor cells through effects on protein 
kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun 2009; 381: 
192-197 
 
34. Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z, Rosen RT. Isolation and 
identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agric. 
Food Chem 2000; 48:253-256 
 
35. Dixon RA, Paiva NL. Stress-induced phenylpropanoid metabolism. Plant 
Cell 1995; 7(7):1085-1097 
 
36. Halls C, Yu O. Potential for metabolic engineering of resveratrol 
biosynthesis. Trends Biotechnol 2008; 26(2):77-81 
 
37. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavaibility 
and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. 
Am J Clin Nutr 2005; 81:230S-242S 
 
Bibliography 
 
 57 
38. Renaud S, De Lorgeril M. Wine, alcohol, platelets, and the French paradox 
for coronary heart disease. Lancet 1992; 339 (8808):1523-6 
 
39. Soleas GJ, Diamandis EP, Goldberg DMJ. Wine as a biological fluid: 
history, production, and role in disease prevention. J Clin Lab Anal. 1997; 
11(5):287-313 
 
40. Ignatowicz E, Baer-Dubowska W. Resveratrol, a natural chemopreventive 
agent against degenerative diseases. Pol J Pharmacol. 2001; 53(6):557-69 
 
41. Petrovski G, Gurusamy N, and Das DK. Resveratrol in cardiovascular health 
and disease. Ann NY Acad Sci 2011; 1215:22-33 
42. Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, Pelegri C, 
Vilaplana J, Beas-Zarate C, Pallàs M. Sirtuin activators: designing molecules to 
extend life span. Biochim Biophys Acta. 2010; 1799(10-12):740-9 
43. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo 
R, Csiszar A. Resveratrol confers endothelial protection via activation of the 
antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010; 
299:H18-H24 
 
44. Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating 
the key enzymes activities of carbohydrate metabolism in streptozotocin-
nicotinamide-induced diabetic rats. Chem Biol Interact 2009; 179:356-362 
 
45. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, Ungvari Z, Zhang C. 
Resveratrol Improves Left Ventricular Diastolic Relaxation in Type 2 Diabetes 
by Inhibiting Oxidative/Nitrative Stress: in vivo Demonstration with Magnetic 
Resonance Imaging. Am J Physiol Heart Circ Physiol 2010; 299:H985-H994 
 
46. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani 
H, Bagchi D, Das DK, and Maulik N. Resveratrol alleviates cardiac dysfunction 
in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme 
oxygenase. Free Radic Biol Med 2007; 43:720-729 
 
47. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M. 
Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase 
and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart 
Circ Physiol 2010; 298:H833-H843 
 
48. Balestrieri ML, Schiano C, Felice F, Casamassimi A, Balestrieri A, Milone L, 
Servillo L, Napoli C. Effect of low doses of red wine and pure resveratrol on 
circulating endothelial progenitor cells. J Biochem 2008; 143:179-186 
 
49. Gurusamy N, Ray D, Lekli I, Das DK. Red wine antioxidant resveratrol-
modified cardiac stem cells regenerate infarcted myocardium. J Cell Mol Med 
2010; 14:2235-2239 
 
50. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search 
for a unifying hypothesis. Circ Res 2006; 98:596-605 
 
Bibliography 
 
 58 
51. Suurmeijer AJ, Clément S, Francesconi A, Bocchi L, Angelini A, Van 
Veldhuisen DJ, Spagnoli LG, Gabbiani G, Orlandi A. Alpha-actin isoform 
distribution in normal and failing human heart: a morphological, morphometric, 
and biochemical study. J Pathol 2003; 99:387-397 
 
52. Myreng Y, Smiseth OA. Assessment of left ventricular relaxation by Doppler 
echocardiography. Comparison of isovolumic relaxation time and transmitral 
flow velocities with time constant isovolumic relaxation. Circulation 1990; 
81:260-266 
 
53. Zaniboni M, Pollard AE, Yang L, Spitzer KW. Beat-to-beat repolarization 
variability in ventricular myocytes and its suppression by electrical coupling. Am 
J Physiol Heart Circ Physiol 2000; 278:H677-H687 
 
55. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, 
Yasuzawa-Amano S, Trofimova I, Siggins RW, Lecapitaine N, Cascapera S, 
Beltrami AP, D'Alessandro DA, Zias E, Quaini F, Urbanek K, Michler RE, Bolli 
R, Kajstura J, Leri A, Anversa P. Human cardiac stem cells. Proc Natl Acad Sci 
U S A 2007; 104:14068-14073 
 
54. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, 
Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, 
Anversa P. Adult cardiac stem cells are multipotent and support myocardial 
regeneration. Cell 2003; 114:763-776 
 
56. Dodge HT, Baxley WA. Left ventricular volume and mass and their 
significance in heart disease. Am J Cardiol 1969; 23:528-537 
 
57. Berni R, Savi M, Bocchi L, Delucchi F, Musso E, Chaponnier C, Gabbiani G, 
Clement S, Stilli D. Modulation of actin isoform expression before the transition 
from experimental compensated pressure-overload cardiac hypertrophy to 
decompensation. Am J Physiol Heart Circ Physiol 2009; 296:H1625-H1632 
 
58. Clément S, Stouffs M, Bettiol E, Kampf S, Krause KH, Chaponnier C, Jaconi 
M. Expression and function of alpha-smooth muscle actin during embryonic-
stem-cell-derived cardiomyocyte differentiation. J Cell Sci 2007; 120:229-238 
 
59. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A 
monoclonal antibody against alpha-smooth muscle actin: a new probe for 
smooth muscle differentiation. J Cell Biol 1986; 103:2787-2796 
 
60. Clément S, Chaponnier C, Gabbiani G. A subpopulation of cardiomyocytes 
expressing alpha-skeletal actin is identified by a specific polyclonal antibody. 
Circ Res 1999; 85:e51-e58 
 
61. Dugina V, Zwaenepoel I, Gabbiani G, Clément S, Chaponnier C. Beta and 
gamma-cytoplasmic actins display distinct distribution and functional diversity. J 
Cell Sci 2009; 122:2980-2988 
 
62. Cohen BH. One-Way Independent ANOVA. In: Explaining Psychological 
Statistics (2nd ed.). Hoboken-NJ: John Wiley & Sons 2001, Inc. pp 324-359 
 
Bibliography 
 
 59 
63. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac 
pathophysiology: a paradigm shift in human myocardial biology. Circ Res 2011; 
109:941-961 
 
64. Picchi A, Capobianco S, Qiu T, Focardi M, Zou X,  Cao JM, Zhang C. 
Coronary microvascular dysfunction in diabetes mellitus: A review. World J 
Cardiol 2010; 2:377-390 
 
65. Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular 
injury in diabetes--part II: cellular mechanisms and therapeutic targets. Vascul 
Pharmacol 2011; 54:75-79 
 
66. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative 
stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol 
2010; 88:233-240 
 
67. Shin SM, Cho IJ, Kim SG. Resveratrol protects mitochondria against 
oxidative stress through AMP-activated protein kinase-mediated glycogen 
synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-
LKB1 pathway. Mol Pharmacol. 2009; 76(4):884-95 
 
68. Park DW, Baek K, Kim JR, Lee JJ, Ryu SH, Chin BR, Baek SH. Resveratrol 
inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen 
species and monocyte chemotactic protein-1. Exp Mol Med 2009; 41:171-179 
 
69. Mukherjee S, Lekli I, Gurusamy N, Bertelli AA, Das DK. Expression of the 
longevity proteins by both red and white wines and their cardioprotective 
components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med 
2009; 46:573-578 
 
70. Yu W, Fu YC, Zhou XH, Chen CJ, Wang X, Lin RB, Wang W. Effects of 
resveratrol on H(2)O(2)-induced apoptosis and expression of SIRTs in H9c2 
cells. J Cell Biochem 2009; 107:741-747 
 
71. Das M, Das DK. Resveratrol and cardiovascular health. Mol Aspects Med 
2010; 31:503-512 
 
72. Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. The cardiovascular 
nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms 
and therapeutic potential. Curr Med Chem 2010; 17:2442-2455 
 
73. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a unique phytoalexin 
present in red wine, delivers either survival signal or death signal to the 
ischemic myocardium depending on dose. Journal of Nutritional Biochemistry 
2009; 20:443-452 
 
74. Pasciu V, Posadino AM, Cossu A, Sanna B, Tavolini B,  Gaspa L, Marchisio 
A, Dessole S, Capobianco G, and Pintus GF. Akt Downregulation by Flavin 
Oxidase–Induced ROS Generation Mediates Dose-Dependent Endothelial Cell 
Damage Elicited by Natural Antioxidants. Toxicological Sciences 2010; 
114:101-112 
 
Bibliography 
 
 60 
75. Albiero M, Menegazzo L, Boscaro E, Agostini C, Avogaro A, Fadini GP. 
Defective recruitment, survival and proliferation of bone marrow-derived 
progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia 
2011; 54:945-953 
 
76. Westermann D,  Van Linthout S, Dhayat S, Dhayat N, Escher F, Bucker-
Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschope C. 
Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting 
Enzyme Inhibition in Experimental Diabetic Cardiomyopathy. Diabetes 2007; 
56:1834-1841 
 
77. Younce CW, Kolattukudy PE. MCP-1 causes cardiomyoblast death via 
autophagy resulting from ER stress caused by oxidative stress generated by 
inducing a novel zinc-finger protein, MCPIP. Biochem J 2010; 426:43-53 
  
78. Bustin M. Regulation of DNA-dependent activities by the functional motifs of 
the high-mobility-group chromosomal proteins. Mol Cell Biol.1999; 19(8):5237-
46 
 
79. Bianchi ME, Beltrame M. Upwardly mobile proteins. Workshop: the role of 
HMG proteins in chromatin structure, gene expression and neoplasia. EMBO 
Rep. 2000; 1(2):109-14 
 
80. Scaffidi P,  Mistelli T, Bianchi ME. Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 2002; 418:191-195.41 
 
81. Andersson U, Wang H, Palmblad K, Aveberger AC, Erlandsson-Harris H, 
Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High Mobility group 1 
protein (HMG-1) stimulates proinflammatory cytokines synthesis in human 
monocytes. J Exp Med 2000; 192:565-570 
 
82. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, 
Strassheim D, Pitts TM, Tracey KJ, Abraham E. Activation of gene  expression 
in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell 
Physiol 2003; 284:C870-C879 
 
83. Hewett TE, Grupp IL, Grupp G, Robbins J. Alpha-skeletal actin is 
associated with increased contractility in the mouse heart. Circ Res 1994; 
74:740-746 
 
84. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, 
Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, 
Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What 
is new for an old molecule? Systematic review and recommendations on the 
use of resveratrol. PLoSONE 2011; 
6:e19881.doi:10.1371/journal.pone.0019881 
 
85. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: 
What formulation solutions to bioavailability limitations? J Control Release 2011; 
doi:10.1016/j.jconrel.2011.09.083 
 
Bibliography 
 
 61 
86. Kanno S, Saffitz JE.  The role of myocardial gap junctions in electrical 
conduction and arrhythmogenesis. Cardiovasc Pathol 2001; 10:169-177 
 
87. Okruhlicova L, Tribulova N, Misejkova M, Kucka M, Stetka R, Slezak J, 
Manoach M. Gap junction remodelling is involved in the susceptibility of diabetic 
rats to hypokalemia-induced ventricular fibrillation. Acta Histochem 2002; 
104:387-391 
 
 
Acknowledgements 
 
 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grazie 
Publications 
 
 64 
 
Publications 
 
1. Stilli D, Lagrasta C, Berni R, Bocchi L , Savi M, Delucchi F, Graiani G, 
Monica M,  Maestri R, Baruffi S, Rossi S, Macchi E, Musso E, Quaini F. 
Preservation of ventricular performance at early stages of diabetic 
cardiomyopahty involves changes in myocyte size, number and intercellular 
coupling. Basic Res Cardiol., 102(6):488-499, 2007 
 
 
2. Murasky JA, Rota M, Misao Y, Fransioli J, Cottage C, Fischer K, Esposito G, 
Delucchi F, Arcarese M, Alvarez R, Siddiqi S, Emanuel GN, Wu W, Gude N, 
Leri A, Kajstura J, Magnuson N, Berns A, Houser SR, Schaefer EM, Anversa P, 
Sussman MA. Pim-1 regulates cardiomyocyte survival downstream of AKT. 
Nature Medicine, 13(12):1467-75, 2007 
 
 
3. Boni A, Urbanek K, Nascimbene A, Hosoda T, Zheng H, Delucchi F, Amano 
K, González A, Vitale S, Ojaimi C, Rizzi R, Bolli R, Yutzey K, Rota M, Kajstura 
J, Anversa P, Leri A. Notch1 regulates the fate of cardiac progenitor cells. Proc 
Natl Acad Sci USA, 105(40):15529-34, 2008 
 
 
4. Berni R, Savi M, Bocchi L, Delucchi F, Musso E, Chaponnier C, Gabbiani G, 
Clement S, Stilli D. Modulation of actin isoform expression before the transition 
from experimental compensated pressure-overload cardiac hypertrophy to 
decompensation. Am J Physiol Heart Circ Physiol, 296(5):H1625-32, 2009 
 
 
5. Colussi C, Berni R, Rosati J, Straino S, Vitale S, Spallotta F, Baruffi S, Bocchi 
L, Delucchi F, Rossi S, Savi M, Rotili D, Quaini F, Macchi E, Stilli D, Musso E, 
Mai A, Gaetano C, Capogrossi MC. The Histone deacetylase inhibitor 
suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic 
mice. Cardiovasc Res. 2010 Feb 17. PMID:20164117  
 
 
6. Urbanek K, Cabral-da-Silva MC, Ide-Iwata N, Maestroni S, Delucchi F, Zheng 
H, Ferriera-Martins J, Ogorek B, D’Amario D, Bauer M, Zerbini G, Rota M, 
Hosoda T, Liao R, Anversa P, Kajstura J, Leri A. Inhibition of Notch1-dependent 
cardiomyogenesis leads to a dilated myopathy in the neonatal heart. Circ Res. 
2010 Aug 6; 107(3):429-41 
 
 
7. Delucchi F, Berni R, Frati C, Cavalli S, Graiani G, Sala R, Chaponnier C, 
Gabbiani G, Lagrasta C, Quaini F, Stilli D. Resveratrol treatment reduces 
cardiac progenitor cell dysfunction and prevents morpho-functional ventricular 
remodeling in type-1 diabetic rats. PLoS One. 2012; Submitted 
 
 
